CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to understand the mechanisms of resistance to BET inhibitors in cancer therapy. By using advanced technologies, it seeks to identify molecular factors that influence sensitivity to these treatments, potentially leading to improved cancer therapies.
Besides DNA mutations, cancers harbor complex aberrations of the epigenetic landscape, which are reversible and amenable to pharmacologic intervention.
Therapeutic targeting of chromatin regulators has shown great promise in first clinical studies, and this has triggered a massive effort to explore this machinery in academic and pharmaceutical research.
Recently, the bromodomain and extraterminal domain (BET) containing protein 4 (BRD4), a reader of histone-acetyl marks, has emerged as a promisi…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
